For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Agilon Health (AGL) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Agilon Health is a member of the Medical sector. This group includes 1012 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst. The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agilon Health is currently sporting a Zacks Rank of #2 (Buy). Within the past quarter, the Zacks Consensus Estimate for AGL's full-year earnings has moved 14.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Our latest available data shows that AGL has returned about 56.8% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 6.7% on average. This means that Agilon Health is outperforming the sector as a whole this year. Akero Therapeutics, Inc. (AKRO) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 63.7%. The consensus estimate for Akero Therapeutics, Inc.'s current year EPS has increased 6.7% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Agilon Health belongs to the Medical Services industry, a group that includes 59 individual stocks and currently sits at #84 in the Zacks Industry Rank. This group has gained an average of 2.5% so far this year, so AGL is performing better in this area. On the other hand, Akero Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry. This 510-stock industry is currently ranked #71. The industry has moved +5.7% year to date. Agilon Health and Akero Therapeutics, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Story Continues Agilon Health, Inc. (AGL):Free Stock Analysis Report Akero Therapeutics, Inc. (AKRO):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...